Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
Date:6/8/2008

the trial is expected to take approximately fourteen months: two months for screening, three months for subject treatment and a further nine months for subject follow-up. Individuals interested in participating in this trial should visit http://www.clinicaltrials.gov/ .

Phase 2 Study of SB-509 to Evaluate Stem Cell Mobilization (SB-509-703)

Twenty subjects will be enrolled in the stem cell mobilization Phase 2 trial. Subjects will be randomized to one of four cohorts with 5 subjects in each cohort. Cohorts 1 and 2 will receive a single treatment of 30 mg into one leg or 60 mg (30 mg in each leg) of SB-509, respectively, by intramuscular (IM) injection on Day 0. Cohort 3 will receive a single treatment of an equal volume of placebo by IM injection into a lower limb on Day 0. Cohort 4 will receive two treatments of 60 mg of SB-509 (30 mg in each leg) by IM injection (Day 0 and 90). Subjects will receive injections in a distribution pattern that targets the major peripheral nerves in the legs and feet.

Peripheral blood samples taken before and at various times post-treatment with SB-509 will be assayed and the numbers of circulating stem cells will be assessed using stem cell-specific enzymatic activity (aldehyde dehydrogenase staining), culture-based assays, as well as assays of cell surface expression of stem cell-specific markers.

The signs and symptoms of diabetic peripheral neuropathy and any changes that occur during the trial will also be evaluated based on neurological examination data (NIS-LL), electrophysiological testing data, subject neurological questionnaire, and subject pain assessment (VASPI). Specifically, investigators will use the following tests: QST with the Vibratron II instrument, to assess the threshold of detection of vibration and electrophysiological testing. A total neuropathy composite score (TNS) will also be computed to evaluate changes in nerve health.
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
2. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
3. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
6. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
7. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
8. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743
9. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
10. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
11. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014 Research and ... Arthritis Drugs Market 2014-2018" report to their offering. ... a chronic disease that leads to inflammation and pain in ... and ankles. In addition, it causes inflammation of the tissues ... The symptoms of RA begin slowly, usually just ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
(Date:7/28/2014)... July 28, 2014 Concord Medical Services Holdings ... CCM ), a leading specialty hospital management solution provider ... diagnostic imaging centers in China , ... of Directors declared a special cash dividend of US$0.30 ... ("ADS")) on the Company,s outstanding ordinary shares. The total ...
Breaking Medicine Technology:Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4Concord Medical Declares Special Dividend 2
... (Nasdaq: BMRN ) today announced the initiation of ... polymerase (PARP) inhibitor in development for the treatment of genetically-defined ... show survival benefits in cancer patients with tumors that have ... agents, and BMN 673 appears to have superior potency, selectivity, ...
... RF Technologies®, a leading provider of radio frequency ... announced a distributor agreement with Universal Hospital Services, ... management and service solutions. Through the agreement, which ... offer the RF Technologies Safe Place® Infant and ...
Cached Medicine Technology:BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 2BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 3RF Technologies® Announces Distributor Agreement With Universal Hospital Services 2
(Date:7/28/2014)... The report “Industrial Enzymes Market by Types ... Agents, Bio-Fuel, Animal Feed), & Geography - Global ... the global industrial enzymes market with analysis and ... It also identifies driving and restraining factors for ... trends, opportunities, burning issues, winning imperatives, and challenges. ...
(Date:7/28/2014)... (Boston)-- Researchers from Boston University School of Medicine (BUSM) ... increase the risk of developing Alzheimer,s disease (AD). The ... new drug treatment options that target PLXNA4 specifically. These ... , AD is the most frequent age-related dementia affecting ... 65 and older, and more than 40 percent of ...
(Date:7/28/2014)... "Fist bumping" transmits significantly fewer bacteria than ... cultural expectation of hand-to-hand contact between patients and ... August issue of the American Journal of ... Association for Professionals in Infection Control and Epidemiology ... of Biological, Environmental, and Rural Sciences at Aberystwyth ...
(Date:7/28/2014)... 2014) -- Researchers from The University of Texas Health Science ... institutions have identified a combination of pills that cures 9 ... drugs sofosbuvir and simeprevir, with or without ribavirin, cured 93 ... by patients, according to the study published today in ... the U.S. , Eric Lawitz, M.D., clinical professor in ...
(Date:7/28/2014)... WA (PRWEB) July 28, 2014 ... consulting and care management organizations, has published a ... low-cost approach to engaging patients and families in ... environments at multiple hospitals, the toolkit provides a ... huddle” with patients and their families early in ...
Breaking Medicine News(10 mins):Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 2Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 3Health News:Industrial Enzymes Market Worth $5,987.5 Million by 2018 - Report by MarketsandMarkets 4Health News:Researchers identify potential biomarker for AD 2Health News:Fist-bumping beats germ-spreading handshake, study reports 2Health News:New pill regimens published in The Lancet cure hardest-to-treat hepatitis C patients 2Health News:Patient Engagement in Hospital Infection Control: Online Toolkit Provides a New Solution 2
... help college students retain and integrate new information to ... abstract that will be presented Tuesday, June 14, in ... of the Associated Professional Sleep Societies LLC (APSS). ... microeconomics test was preserved after a 12-hour period that ...
... Getting six to nine hours of sleep per night is ... ratings for depression, suggests a research abstract that will be ... the 25th Anniversary Meeting of the Associated Professional Sleep Societies ... sleep duration of six to nine hours per night had ...
... , MONDAY, June 13 (HealthDay News) -- Spending ... increased overall and especially among certain groups of patients, a ... aged 18 and older who used glaucoma medication between 2001 ... medications increased from $445 in 2001 to $557 in 2006. ...
... Ill. June 13, 2011 A new ... preparation are associated with relatively high adenoma (precancerous ... substantially decreases colonoscopy effectiveness and may mandate an ... context of suboptimal bowel preparation, of all adenomas ...
... National Institutes of Health researchers have identified a new pathway ... The study provides insights about the interaction between a toxic ... chromosomes like aglets, the plastic tips that bind the ends ... National Human Genome Research Institute (NHGRI) appears in the June ...
... China? Boys are considered a greater asset for farming, but ... want a boy at any cost doubled? Sociologist ... families in China choose to abort girls. When ... born in China, a nationwide campaign was started against sex-selective ...
Cached Medicine News:Health News:Sleep can boost classroom performance of college students 2Health News:The good life: Good sleepers have better quality of life and less depression 2Health News:Polyp miss rates high for colonoscopies done after poor bowel preparation 2Health News:Polyp miss rates high for colonoscopies done after poor bowel preparation 3Health News:Polyp miss rates high for colonoscopies done after poor bowel preparation 4Health News:NIH researchers find new clues about aging 2Health News:NIH researchers find new clues about aging 3Health News:NIH researchers find new clues about aging 4Health News:Has China's campaign against female feticide done more harm than good? 2
... is a threaded titanium anchor, ... procedures. The anchor features wide ... to optimize bone purchase, as ... to prevent suture binding. Fastin ...
... 5mm Super Revo Suture Anchor offers a ... a mini-open rotator cuff repair. The cutting ... is pre-threaded with two #2 strands of ... suture management are avoided with the Independent ...
... 5mm Super Revo Suture Anchor offers a ... a mini-open rotator cuff repair. The cutting ... is pre-threaded with two #2 strands of ... suture management are avoided with the Independent ...
The Linvatec UltraFix Suture Anchor System's smooth surface until deployed eliminates tissue, bone and suture damage and its ultra smooth eyelet hole preserves suture integrity....
Medicine Products: